Maurizio Mansutti, MD

Articles by Maurizio Mansutti, MD

Gemcitabine/Epirubicin/Paclitaxel Trials in Advanced Breast Cancer

ByPierfranco Conte, MD,Barbara Salvadori, MD,Sara Donati, MD,Alessandra Gennari, MD,Gian Luigi Cetto, MD,Annamaria Molino, MD,Lucio CrinÒ, MD,Francesca Mazzoni, MD,Enzo Galligioni, MD,Maurizio Mansutti, MD

February 1st 2001

Numerous trials have shown that the pharmacokinetic interferences of epirubicin (Ellence)/paclitaxel (Taxol) combinations produce less pharmacodynamic effect than doxorubicin/paclitaxel regimens. Paclitaxel is more easily

Latest Updated Articles

Gemcitabine/Epirubicin/Paclitaxel Trials in Advanced Breast Cancer
Published: February 1st 2001 | Updated:

Maurizio Mansutti, MD

Articles by Maurizio Mansutti, MD

Gemcitabine/Epirubicin/Paclitaxel Trials in Advanced Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment